Safety of Rifampicin at High Dose for Difficult-to-Treat Tuberculosis: Protocol for RIAlta Phase 2b/c Trial

Previous clinical trials for drug-susceptible tuberculosis (DS-TB) have shown that first-line treatment with doses of rifampicin up to 40 mg/kg are safe and increase the early treatment response for young adults with pulmonary tuberculosis. This may lead to a shorter treatment duration for those per...

Descripción completa

Detalles Bibliográficos
Autores principales: Espinosa-Pereiro, Juan, Ghimire, Samiksha, Sturkenboom, Marieke G. G., Alffenaar, Jan-Willem C., Tavares, Margarida, Aguirre, Sarita, Battaglia, Arturo, Molinas, Gladys, Tórtola, Teresa, Akkerman, Onno W., Sanchez-Montalva, Adrian, Magis-Escurra, Cecile
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9864493/
https://www.ncbi.nlm.nih.gov/pubmed/36678638
http://dx.doi.org/10.3390/pharmaceutics15010009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9864493/
https://www.ncbi.nlm.nih.gov/pubmed/36678638
http://dx.doi.org/10.3390/pharmaceutics15010009

Ejemplares similares